Literature DB >> 11500334

Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction.

A O'Brien1, P Russo-Magno, A Karki, S Hiranniramol, M Hardin, M Kaszuba, C Sherman, S Rounds.   

Abstract

Inhaled corticosteroid therapy has proven efficacy for asthmatics, but the benefit for patients with chronic obstructive pulmonary disease (COPD) is less well supported. We hypothesized that withdrawal of inhaled steroids in elderly patients with severe irreversible airway obstruction would not lead to a deterioration in respiratory function. We designed a prospective, double-blind, randomized, placebo-controlled, crossover study to follow spirometry, quality of life questionnaire, six-minute (6-min) walk test, and sputum markers of inflammation during a 6-wk placebo treatment period and a 6-wk treatment period with beclomethasone dipropionate (BDP), 336 microg/d. There were 24 men receiving BDP who entered the study; 15 completed the study. Their mean age was 66.9 +/- 1.9 yr, and mean FEV(1) was 1.61 +/- 0.1 L (47% of predicted). There was a significant decrease in the mean FEV(1 )while using the placebo inhaler (1.70 L versus 1.60 L, baseline versus placebo: 95% CI, 0.002 to 0.195; p < 0.05). There was a decrease in the mean percentage change in FEV(1) for the study subjects during the placebo treatment period as compared with the BDP treatment period (-6.28 versus 5.03%, placebo versus BDP: 95% CI, -23.38 to 0.76; p = 0.06). Six-minute walk test results and sputum analysis for cell count and differential were not significantly different during placebo and BDP treatment periods. Borg scale assessment of dyspnea after exercise was increased while using the placebo inhaler as compared with baseline, and decreased during the BDP treatment period. Chronic Respiratory Disease Questionnaire (CRQ) scores revealed no significant difference between placebo and BDP. This study has demonstrated that in elderly patients with severe irreversible airway obstruction, withdrawal of inhaled corticosteroid therapy leads to a deterioration in ventilatory function and increased exercise-induced dyspnea.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11500334     DOI: 10.1164/ajrccm.164.3.2002052

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  23 in total

1.  Appropriateness of Triple Therapy after COPD Exacerbation.

Authors:  John R Manderville
Journal:  Can J Hosp Pharm       Date:  2013-01

Review 2.  Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease.

Authors:  Marcel Bonay; Catherine Bancal; Bruno Crestani
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.

Authors:  E F M Wouters; D S Postma; B Fokkens; W C J Hop; J Prins; A F Kuipers; H R Pasma; C A J Hensing; E C Creutzberg
Journal:  Thorax       Date:  2005-06       Impact factor: 9.139

4.  Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease.

Authors:  J van der Palen; E Monninkhof; P van der Valk; S D Sullivan; D L Veenstra
Journal:  Thorax       Date:  2005-10-21       Impact factor: 9.139

Review 5.  Systematic review of inhaled corticosteroid withdrawal effects in chronic obstructive pulmonary disease, and comparison with two "real-life" studies.

Authors:  Wenjing Ye; Xuejun Guo; Tianyun Yang; Fengfeng Han
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 6.  Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices.

Authors:  Eric Derom; Romain A Pauwels
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 7.  Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?

Authors:  S F Paul Man; Don D Sin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium.

Authors:  Donald P Tashkin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-02-18

Review 9.  Inhaled corticosteroids in the long-term management of patients with chronic obstructive pulmonary disease.

Authors:  Don D Sin; S F Paul Man
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  [Pulmonary diseases in the elderly. Problems of pharmacotherapy].

Authors:  D Ukena
Journal:  Internist (Berl)       Date:  2003-08       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.